BiotechTube

Aflibercept (2.0 mg)

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Macular Edema With Central Retinal Vein Occlusions

Conditions

Macular Edema With Central Retinal Vein Occlusions

Trial Timeline

Jun 1, 2013 → Aug 1, 2016

NCT ID
NCT01870427

About Aflibercept (2.0 mg)

Aflibercept (2.0 mg) is a approved stage product being developed by Regeneron Pharmaceuticals for Macular Edema With Central Retinal Vein Occlusions. The current trial status is completed. This product is registered under clinical trial identifier NCT01870427. Target conditions include Macular Edema With Central Retinal Vein Occlusions.

What happened to similar drugs?

20 of 20 similar drugs in Macular Edema With Central Retinal Vein Occlusions were approved

Approved (20) Terminated (3) Active (0)
✅FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
✅FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
✅Aflibercept Injection [Eylea]Santen PharmaceuticalApproved
✅Ozurdex + AfliberceptAbbVieApproved
✅RanibizumabNovartisApproved
✅ranibizumabNovartisApproved
✅intravitreal injection of Brolucizumab 6 mg in study eyeNovartisApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01870427ApprovedCompleted

Competing Products

20 competing products in Macular Edema With Central Retinal Vein Occlusions

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
25
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
4 mg CLS-TA + Sham + IVT afliberceptClearside BiomedicalPhase 2
25
suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or AvastinClearside BiomedicalPhase 3
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
KVD001 InjectionKalVista PharmaceuticalsPhase 2
29
KVD001 InjectionKalVista PharmaceuticalsPhase 1
23
FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
33
FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
33
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
UBX1325Unity BiotechnologyPhase 2
25
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
25
UBX1325Unity BiotechnologyPhase 1
19
CT-P42 + EyleaCelltrionPhase 3
40
Faricimab + AfliberceptChugai PharmaceuticalPhase 3
40
Faricimab + AfliberceptChugai PharmaceuticalPhase 3
40
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Fovista® + bevacizumab + ranibizumab + afliberceptAstellas PharmaPhase 2
27
MA09-hRPEAstellas PharmaPre-clinical
26